Moonage Media Review: Clearmind's MEAI and GLP-1 - Are These the Next-Generation Treatment for Weight Loss?
Clearmind Medicine Inc. - Common Shares (CMND)
NASDAQ:AMEX Investor Relations:
ir.manitowocfoodservice.com/investor-relations/default.aspx
Company Research
Source: PR Newswire
HONG KONG, Feb. 19, 2026 /PRNewswire/ -- As the multi-billion-dollar obesity treatment market continues to search for new therapeutic approaches beyond GLP-1–based treatments, Clearmind Medicine (Nasdaq: CMND), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, recently reported additional progress related to its proprietary, non-hallucinogenic neuroplastogen, MEAI.In a world where obesity affects over a billion people globally, the search for truly transformative weight loss solutions has never been more urgent. Current blockbuster drugs like semaglutide and tirzepatide have revolutionized the treatment landscape by targeting gut-derived hormones that regulate appetite and metabolism. However, published studies and post-marketing experience indicate that these therapies may be associated, in certain patients, with gastrointestinal side effects, lean mass loss, tolerabilit
Show less
Read more
Impact Snapshot
Event Time:
CMND
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CMND alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CMND alerts
High impacting Clearmind Medicine Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
CMND
News
- Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval [Yahoo! Finance]Yahoo! Finance
- Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board ApprovalGlobeNewswire
- Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical TrialGlobeNewswire
- Clearmind Medicine Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic Neuroplastogen MEAIGlobeNewswire
- Excellent Achievements for Clearmind’s Proprietary MEAI that was Included in U.S. Congress’ Emerging Therapies Bill to Expand Veteran Access to Innovative TreatmentsGlobeNewswire
CMND
Sec Filings
- 3/4/26 - Form 6-K
- 2/27/26 - Form EFFECT
- 2/17/26 - Form F-3
- CMND's page on the SEC website